143 related articles for article (PubMed ID: 33998238)
1. Features and impacts on the prognosis of gene mutations in patients with acute myeloid leukemia.
Wu M; Guo ZW; Huang GN; Ye YB
Neoplasma; 2021 Sep; 68(5):1072-1078. PubMed ID: 33998238
[TBL] [Abstract][Full Text] [Related]
2. Next-generation sequencing reveals gene mutations landscape and clonal evolution in patients with acute myeloid leukemia.
Chen X; Zhu H; Qiao C; Zhao S; Liu L; Wang Y; Jin H; Qian S; Wu Y
Hematology; 2021 Dec; 26(1):111-122. PubMed ID: 33491606
[TBL] [Abstract][Full Text] [Related]
3. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
4. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.
Sallman DA; Komrokji R; Vaupel C; Cluzeau T; Geyer SM; McGraw KL; Al Ali NH; Lancet J; McGinniss MJ; Nahas S; Smith AE; Kulasekararaj A; Mufti G; List A; Hall J; Padron E
Leukemia; 2016 Mar; 30(3):666-73. PubMed ID: 26514544
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and prognostic significance of genetic mutations in acute myeloid leukemia based on a targeted next-generation sequencing technique.
Wang RQ; Chen CJ; Jing Y; Qin JY; Li Y; Chen GF; Zhou W; Li YH; Wang J; Li DW; Zhao HM; Wang BH; Wang LL; Wang H; Wang MZ; Gao XN; Yu L
Cancer Med; 2020 Nov; 9(22):8457-8467. PubMed ID: 32970934
[TBL] [Abstract][Full Text] [Related]
6. Molecular characterization of AML-MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC-defining criteria, TP53 allelic state, or TP53 variant allele frequency.
Zhao D; Eladl E; Zarif M; Capo-Chichi JM; Schuh A; Atenafu E; Minden M; Chang H
Cancer Med; 2023 Mar; 12(6):6511-6522. PubMed ID: 36394085
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic significance of different IDH mutations and accompanying gene mutations in patients with acute myeloid leukemia].
Wu RY; Xie XS; Wei Y; Jang ZX; Chen DD; Sun H; Wan DM; Liu YF; Sun L
Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):39-44. PubMed ID: 33677867
[No Abstract] [Full Text] [Related]
8. Usefulness of BCOR gene mutation as a prognostic factor in acute myeloid leukemia with intermediate cytogenetic prognosis.
Terada K; Yamaguchi H; Ueki T; Usuki K; Kobayashi Y; Tajika K; Gomi S; Kurosawa S; Saito R; Furuta Y; Miyadera K; Tokura T; Marumo A; Omori I; Sakaguchi M; Fujiwara Y; Yui S; Ryotokuji T; Arai K; Kitano T; Wakita S; Fukuda T; Inokuchi K
Genes Chromosomes Cancer; 2018 Aug; 57(8):401-408. PubMed ID: 29663558
[TBL] [Abstract][Full Text] [Related]
9. Clinical and molecular characteristics of acute myeloid leukemia and the dismal prognosis of
Liu H; Shi Y; Tao S; Li Y; Wang C; Yu L
Hematology; 2023 Dec; 28(1):2223866. PubMed ID: 37313982
[TBL] [Abstract][Full Text] [Related]
10. RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.
Gaidzik VI; Teleanu V; Papaemmanuil E; Weber D; Paschka P; Hahn J; Wallrabenstein T; Kolbinger B; Köhne CH; Horst HA; Brossart P; Held G; Kündgen A; Ringhoffer M; Götze K; Rummel M; Gerstung M; Campbell P; Kraus JM; Kestler HA; Thol F; Heuser M; Schlegelberger B; Ganser A; Bullinger L; Schlenk RF; Döhner K; Döhner H
Leukemia; 2016 Nov; 30(11):2160-2168. PubMed ID: 27137476
[TBL] [Abstract][Full Text] [Related]
11. A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice.
Lin PH; Li HY; Fan SC; Yuan TH; Chen M; Hsu YH; Yang YH; Li LY; Yeh SP; Bai LY; Liao YM; Lin CY; Hsieh CY; Lin CC; Lin CH; Lien MY; Chen TT; Ni YH; Chiu CF
Cancer Med; 2017 Feb; 6(2):349-360. PubMed ID: 28070990
[TBL] [Abstract][Full Text] [Related]
12. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
13. [Correlation between myeloperoxidase expression and gene alterations and prognosis in acute myeloid leukemia].
Dong XY; Li YL; Jiang L; Wu CY; Shang BJ; Zhang L; Cheng W; Zhu ZM
Zhonghua Xue Ye Xue Za Zhi; 2019 Jan; 40(1):40-45. PubMed ID: 30704227
[No Abstract] [Full Text] [Related]
14. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.
Morita K; Kantarjian HM; Wang F; Yan Y; Bueso-Ramos C; Sasaki K; Issa GC; Wang S; Jorgensen J; Song X; Zhang J; Tippen S; Thornton R; Coyle M; Little L; Gumbs C; Pemmaraju N; Daver N; DiNardo CD; Konopleva M; Andreeff M; Ravandi F; Cortes JE; Kadia T; Jabbour E; Garcia-Manero G; Patel KP; Futreal PA; Takahashi K
J Clin Oncol; 2018 Jun; 36(18):1788-1797. PubMed ID: 29702001
[TBL] [Abstract][Full Text] [Related]
15. The prognostic impact of reduced variant burden in elderly patients with acute myeloid leukemia treated with decitabine.
Kim M; Kim T; Ahn SY; Lee JH; Park JH; Shin MG; Jung SH; Song GY; Yang DH; Lee JJ; Choi SH; Kim MY; Ahn JS; Kim HJ; Kim DDH
Korean J Intern Med; 2023 Jul; 38(4):534-545. PubMed ID: 37291838
[TBL] [Abstract][Full Text] [Related]
16. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
Thol F; Gabdoulline R; Liebich A; Klement P; Schiller J; Kandziora C; Hambach L; Stadler M; Koenecke C; Flintrop M; Pankratz M; Wichmann M; Neziri B; Büttner K; Heida B; Klesse S; Chaturvedi A; Kloos A; Göhring G; Schlegelberger B; Gaidzik VI; Bullinger L; Fiedler W; Heim A; Hamwi I; Eder M; Krauter J; Schlenk RF; Paschka P; Döhner K; Döhner H; Ganser A; Heuser M
Blood; 2018 Oct; 132(16):1703-1713. PubMed ID: 30190321
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
[TBL] [Abstract][Full Text] [Related]
18. CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis.
Awad MM; Aladle DA; Abousamra NK; Elghannam DM; Fawzy IM
Hematology; 2013 Mar; 18(2):61-8. PubMed ID: 22990006
[TBL] [Abstract][Full Text] [Related]
19. [Using next generation sequencing technology to analyze gene mutations in patients with acute myeloid leukemia and the impact on prognosis].
Zhao CX; Wang JM; Li JM; Zou SH; Chen FY; Liang AB; Hou J; Hu XX; Zhang YX; Gu SY; Zhu JY; Li P; Du J; Yang YN; Qin YW; Wang XR; Wang C
Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(40):3145-3151. PubMed ID: 31694105
[No Abstract] [Full Text] [Related]
20. Development of TP53 mutations over the course of therapy for acute myeloid leukemia.
Alwash Y; Khoury JD; Tashakori M; Kanagal-Shamanna R; Daver N; Ravandi F; Kadia TM; Konopleva M; Dinardo CD; Issa GC; Loghavi S; Takahashi K; Jabbour E; Guerra V; Kornblau S; Kantarjian H; Short NJ
Am J Hematol; 2021 Nov; 96(11):1420-1428. PubMed ID: 34351647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
